

NEURONET: Efficiently Networking European Neurodegeneration Research

Carlos Díaz

Alzheimer Europe Conference 2019, The Hague

www.imi-neuronet.org



Neurodegenerative Disorders: Conditions that result in the progressive loss of brain cells (neurons). Alzheimer's disease and Parkinson's disease are two common neurodegenerative disorders, but there are many others.


Innovative Medicines Initiative (IMI): The world's biggest public-private partnership in the life sciences. It is a partnership between the European Union and the European pharmaceutical industry to work together to develop new vaccines, medicines and treatments.

Consortium: A group made up of independent organisations (for example: universities, pharmaceutical companies, patient groups, etc) that agree to work together to achieve a common objective.

NEURONET is a new IMI initiative aiming to support and better integrate projects in the **IMI Neurodegenerative Disorders portfolio**.

The main aim of NEURONET is to set up an efficient **platform to boost synergy and collaboration across the IMI projects of the Neurodegenerative Disorders portfolio**, assisting in identifying gaps, multiplying its impact, enhancing its visibility and facilitating dovetailing with related initiatives in Europe and worldwide.


Connections



NEURONET acts as a 'switchboard'



NEURONET collects information (e.g. results, resources) and establishes just-in-time connections among project components.



Connecting:

- Tools
- Technologies
- Methodologies
- Expertise
- Data
- Other results

NEURONET Project structure



- Core NEURONET partners
- Acting upon advice of the SCB for decision making and practical implementation
- Responsible for decisions on resource allocation and priorities

IMI Neurodegeneration projects



- High-level, overarching scientific board
- Leaders of all IMI ND projects (EFPIA or Academia).
- Overall scientific strategy
- Creates WGs and TFs
- Advises on prioritisation and sourcing of synergies

NEURONET will leverage existing expertise through different structures:

- ✓ SCB – for overall strategy
- ✓ WG – for expert knowledge on technical areas
- ✓ TF – for targeted effort implementation

- Small cross-project teams
- Specific plan to implement synergies
- Tangible results in a limited time frame
- Pre-defined milestones acting as kill-points

- Thematic, standing working groups
- Formed by expert members from the projects, plus invited experts
- Discuss guidelines and white papers
- Recommend creation of TFs pertaining to their area

Specific synergies

NEURONET

Collaboration and alignment

Invited experts

- Other initiatives
- Stakeholder rep groups

The Scientific Coordination Board

The SCB is formed by the leaders of 15 IMI neurodegeneration projects and provides expert guidance and recommendations in terms of **scientific and strategic evaluation of synergies and priority areas.**



Scientific Coordination Board members:

- Martin Hofmann-Apitius (AETIONOMY)
- Margot Bakker (ADAPTED)
- José Luis Molinuevo (AMYPAD)
- Pieter Jelle Visser (EMIF)
- Craig Ritchie (EPAD)
- Malcolm Macleod (EQIPD)
- Dominique Lesuisse/Zameel Cader (IM2PACT)
- George Tofaris (IMPRiND)
- Mercè Boada (MOPEAD)
- Jochen Prehn (PD-MITOQUANT)
- Andreas Ebner (PHAGO)
- Hugh Marston (PRISM)
- Dag Aarsland (RADAR-AD)
- Matthew Hotopf (RADAR-CNS)
- John Gallacher (ROADMAP)

WG1. Data sharing and re-use

WG2. HTA/regulatory interaction

WG3. Patient privacy and ethics

WG4. Sustainability

PURPOSE OF THE WORKING GROUPS:

- Share lessons learnt
- Re-use work done
- Discuss common challenges & needs
- Identify priorities and opportunities for synergy and collaboration across projects

EXPECTED RESULTS:

- More consistent & informed decision-making
- Improved re-use of results
- Enhanced networking across projects
- Exposure of expert knowledge
- Homogeneous application of standards

Follow NEURONET news & updates on Twitter



@IMI2_NEURONET



Neuronet

@IMI2_NEURONET

Setting up an efficient platform to boost synergy and collaboration across @IMI_JU #Neurodegenerative #Diseases research projects. bit.ly/NeuronetNewsle...

📍 EU/EFPIA IMI2 JU grant n821513 🔗 imi-neuronet.org 📅 Joined March 2019

646 Following 484 Followers



Neuronet @IMI2_NEURONET · Sep 13

The Neuronet programme is celebrating @IMI_JU's public-private partnerships in #neurodegeneration research.

We'll publish a series of Twitter cards and link to insights on projects and collaborators.

Keep an eye on: #WeAreNeuronet

bit.ly/WeAreNeuronet-...





This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821513. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and Parkinson's UK.

www.imi-neuronet.org

